

May 28, 2026

To,  
The Manager  
Listing Compliance Department  
National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai - 400051, Maharashtra, India

NSE Symbol: SHRIAHIMSA; ISIN: INE0DM401012

**Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors took note of and approved developments/enhancements in relation to the upcoming manufacturing plant of the Company's Wholly Owned Subsidiary Shri Ahimsa Healthcare Private Limited situated at Sawarda, Jaipur ("Project") and has considered the same as a material event pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The details of material points are attached herewith as "**Annexure A**".

**Thanking You,**

**Yours faithfully,**  
**for Shri Ahimsa Naturals Limited**

**Aayushi Jain**  
**M. No: A55028**  
**Company Secretary and Compliance Officer**

*Encl: As above*

**“Annexure-A”**

**Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Update on Manufacturing Plant at Sawarda, Jaipur**

The Board of Directors of the Company took note of and approved certain developments/enhancements in relation to the upcoming manufacturing plant of the Company's Wholly Owned Subsidiary Shri Ahimsa Healthcare Private Limited situated at Sawarda, Jaipur (“Project”), considered as a material event pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In furtherance to the ongoing implementation of the Project, the Board approved the integration of the following additional facilities and processes into the plant infrastructure:

1. Decaffeination Process
2. Green Coffee Bean Extract (GCE) Enrichment Process
3. Fungible Botanical Extraction Process
4. Plant Automation Systems

The aforesaid facilities/processes shall be integrated with the existing plant design and are expected to significantly enhance the overall operational capabilities, process efficiencies and long-term scalability of the Project.

The Board further noted that the proposed enhancements would entail an additional capital expenditure of up to ₹70 Crores, proposed to be funded through the following sources:

Particulars	Amount (₹ in Crores)
Capital raise through preferential allotment of Equity Shares/Warrants	32.57
Bank Term Loan	25.00
Internal Accruals	12.43
Total	70.00

The above enhancements are expected to result in multiple strategic and operational benefits for the Company, inter alia, including:

- substantial cost optimisation and savings;
- improved raw material security and backward integration;
- higher production and capacity utilisation efficiencies;
- expansion and diversification of product portfolio; and
- enhancement in overall operational efficiency through automation and integrated processing capabilities.

The Board also took note of the revised implementation schedule of the Project and noted that the commissioning of the said plant is now expected by March, 2027.